CTLA4 and neoplasm: Overall, the flow cytometric and immunohistochemical analyses supported the uptake pattern of [64Cu]NOTA-CD8a in CT26 tumor-bearing mice subjected to XRT alone or in combination with anti-CTLA-4 therapy.